- Home
- IOVA
as 11-15-2024 4:00pm EST
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | SAN CARLOS |
| Market Cap: | 3.0B | IPO Year: | N/A |
| Target Price: | $23.33 | AVG Volume (30 days): | 7.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.44 - $18.33 | Next Earning Date: | 11-07-2024 |
| Revenue: | $90,858,000 | Revenue Growth: | 12751.20% |
| Revenue Growth (this year): | 13827.67% | Revenue Growth (next year): | 183.70% |
Latest Iovance Biotherapeutics Inc. News
IOVA Breaking Stock News: Dive into IOVA Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
Simply Wall St.
6 days ago
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Zacks
7 days ago
IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
GuruFocus.com
7 days ago
Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
Zacks
8 days ago
Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
Associated Press Finance
8 days ago
Iovance Biotherapeutics: Q3 Earnings Snapshot
GlobeNewswire
8 days ago
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
Simply Wall St.
10 days ago
High Growth Tech Stocks to Watch in November 2024
Compare IOVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IOVA Iovance Biotherapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.